Meta-Analysis
Copyright ©The Author(s) 2021.
World J Hepatol. Feb 27, 2021; 13(2): 242-260
Published online Feb 27, 2021. doi: 10.4254/wjh.v13.i2.242
Table 4 Subgroup-specific pooled estimates of occult hepatitis C virus infection prevalence among patients with chronic liver diseases across the Middle Eastern and Eastern Mediterranean countries
VariablesNumber of studiesSample sizesOCI prevalence across studies
Pooled OCI prevalence (%)
Heterogeneity
Range (%)
Median
Mean (%)
95%CI
Cochran’s Q
I-squared (%)
Countries
Egypt516893.91-44.4411.3316.085.81-37.35152.4a97.4
Iran52720-32.0810.1411.463.64-30.7316.6b76.0
Pakistan1104--0.4800.03-7.15--
Temporal duration1
Before 201585230-44.4410.4611.834.84-26.1446.0a84.8
2015 and thereafter315423.91-34.8211.3312.283.23-36.99111.1a98.2
Method of HCV RNA detection
RT-nested PCR63590-44.4421.1121.3811.73-35.7530.5a83.6
Real time RT-PCR416360-11.337.356.292.73-13.8423.9a87.4
RT-PCR170--12.866.83-22.90--
Patients’ subpopulation
Post-HCV non-viremic cases2517160-34.8211.339.143.02-24.53116.8a96.6
Cryptogenic liver diseases342128.89-44.4421.1120.816.87-48.3522.6a86.7
Chronic HCV infection and Cryptogenic liver diseases2,31102--10.786.07-18.43--
Autoimmune hepatitis135--1.390.09-18.67--
Patients’ HCV serostatus
Seronegative52470-44.4410.1416.135.41-39.2827.7a85.6
Seropositive517160-34.8211.339.112.97-24.69116.8a96.6
Seronegative/seropositive1102--10.786.07-18.43--
Sample size
Less than 10063170-44.4411.5015.636.08-34.6732.2a84.5
100 and above517480-34.8210.788.883.04-23.26116.0a96.5
All studies1120650-44.4410.7812.045.87-23.10179.3a94.4